[go: up one dir, main page]

MA28526B1 - Comprimes solubles contenant licarbazepine - Google Patents

Comprimes solubles contenant licarbazepine

Info

Publication number
MA28526B1
MA28526B1 MA29379A MA29379A MA28526B1 MA 28526 B1 MA28526 B1 MA 28526B1 MA 29379 A MA29379 A MA 29379A MA 29379 A MA29379 A MA 29379A MA 28526 B1 MA28526 B1 MA 28526B1
Authority
MA
Morocco
Prior art keywords
tablets containing
soluble tablets
licarbazepine
containing licarbazepine
soluble
Prior art date
Application number
MA29379A
Other languages
English (en)
Inventor
Oskar Kalb
Marie-Christine Wolf
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0406381A external-priority patent/GB0406381D0/en
Priority claimed from GB0406737A external-priority patent/GB0406737D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA28526B1 publication Critical patent/MA28526B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA29379A 2004-03-22 2006-10-11 Comprimes solubles contenant licarbazepine MA28526B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0406381A GB0406381D0 (en) 2004-03-22 2004-03-22 Organic compounds
GB0406737A GB0406737D0 (en) 2004-03-25 2004-03-25 Organic compounds

Publications (1)

Publication Number Publication Date
MA28526B1 true MA28526B1 (fr) 2007-04-03

Family

ID=34962439

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29379A MA28526B1 (fr) 2004-03-22 2006-10-11 Comprimes solubles contenant licarbazepine

Country Status (16)

Country Link
US (1) US20070190143A1 (fr)
EP (1) EP1729737A1 (fr)
JP (1) JP2007529563A (fr)
AR (1) AR048672A1 (fr)
AU (1) AU2005226909B2 (fr)
BR (1) BRPI0509014A (fr)
CA (1) CA2558307A1 (fr)
EC (1) ECSP066872A (fr)
IL (1) IL177830A0 (fr)
MA (1) MA28526B1 (fr)
MX (1) MXPA06010809A (fr)
NO (1) NO20064783L (fr)
PE (1) PE20060124A1 (fr)
RU (1) RU2006137329A (fr)
TW (1) TW200534859A (fr)
WO (1) WO2005092290A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
AR048318A1 (es) * 2004-03-22 2006-04-19 Novartis Ag Formulaciones de matriz orales que comprenden licarbazepina
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
ES2534560T3 (es) * 2005-05-06 2015-04-24 Bial-Portela & Ca, S.A. Acetato de eslicarbazepina y su uso
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
MX350531B (es) * 2010-12-31 2017-09-08 BIAL PORTELA & Cª S A Granulados que comprenden acetato de eslicarbazepina.
JP2013237676A (ja) * 2013-06-26 2013-11-28 Bial-Portela & Ca Sa 酢酸エスリカルバゼピン及び使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH649080A5 (de) * 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
IL125244A (en) * 1998-07-07 2002-12-01 Yissum Res Dev Co Pharmaceutical compositions containing low-melting waxes
GB9925962D0 (en) * 1999-11-02 1999-12-29 Novartis Ag Organic compounds
US20030190343A1 (en) * 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
HRP20041193A2 (en) * 2002-05-31 2005-06-30 Desitin Arzneimittel Gmbh Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
US20050214388A1 (en) * 2004-02-18 2005-09-29 Gorham Thomas R Multivitamin formulations containing controlled-release magnesium
AR048318A1 (es) * 2004-03-22 2006-04-19 Novartis Ag Formulaciones de matriz orales que comprenden licarbazepina

Also Published As

Publication number Publication date
IL177830A0 (en) 2006-12-31
ECSP066872A (es) 2006-11-24
NO20064783L (no) 2006-12-15
AU2005226909B2 (en) 2009-05-14
PE20060124A1 (es) 2006-03-07
MXPA06010809A (es) 2006-12-15
US20070190143A1 (en) 2007-08-16
BRPI0509014A (pt) 2007-08-07
CA2558307A1 (fr) 2005-10-06
EP1729737A1 (fr) 2006-12-13
WO2005092290A1 (fr) 2005-10-06
TW200534859A (en) 2005-11-01
RU2006137329A (ru) 2008-06-20
AU2005226909A1 (en) 2005-10-06
JP2007529563A (ja) 2007-10-25
AR048672A1 (es) 2006-05-17

Similar Documents

Publication Publication Date Title
DE602005026188D1 (de) Medikamentenspender
DE602005001560D1 (de) Zugangskanüle
DE602005016579D1 (de) Abgabevorrichtung
ZA200703312B (en) Pharmaceutical compounds
IS8197A (is) Fjöllaga munnlausnartafla
DK1725218T3 (da) Farmaceutisk sammensætning omfattende pimobendan
MA28801B1 (fr) Composition antihistaminique
IL181229A0 (en) Noncardiotoxic pharmaceutical compounds
DK1757293T3 (da) Bh4-responsiv hyperphenylalaninæmi-medikamenter
DE602004014804D1 (de) Haltenden tabletten
MA28526B1 (fr) Comprimes solubles contenant licarbazepine
MA28527B1 (fr) Formulations orales contenant licarbazepine
DK2918286T3 (da) En farmaceutisk formulering
DE60329865D1 (de) Tablettenfüllvorrichtung
DK1684688T3 (da) Pilledispenser
ITMI20041447A1 (it) Composizione farmaceutica comprendente gabapentina
GB0424742D0 (en) Pharmaceutical compounds
ITMI20040943A1 (it) Composizione farmaceutica cicatrizzante
GB0428554D0 (en) Pharmaceutical compounds
DK1720557T3 (da) Hurtig-opløselig, smagsmaskeret tablet
DE112004001429D2 (de) Pharmazeutischer Wirkstoff
DE502005005982D1 (de) Etikettenspender
ATA16852004A (de) Tablette
UA10369S (uk) Таблетка фармацевтична
SE0400990D0 (sv) Läkemedel